4-(2-溴乙氧基)苯甲腈 | 37142-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-溴乙氧基)苯甲腈
• 英文名称: 4-(2-bromoethoxy)benzonitrile
• 英文别名: 2-(4-cyano-phenoxy)ethyl bromide
• CAS: 37142-39-5
• 化学式: C₉H₈BrNO
• mdl: MFCD04125745
• 分子量: 226.073
• InChiKey: IVKAPFWKLFIYCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(2-Bromoethoxy)benzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(2-Bromoethoxy)benzonitrile
CAS number: 37142-39-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrNO
Molecular weight: 226.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-溴乙氧基)苯甲腈 在 sodium hydrogen sulfide 、 一水合肼 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 tert-butyl {2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]ethoxy}carbamate
  参考文献：
  名称：

  [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
  [FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS

  摘要：

  本发明涉及式(I)的新型β-内酰胺化合物，它们的制备和使用。特别是，本发明涉及作为抗菌剂有用的新型β-内酰胺化合物，即取代脒的单巴坦衍生物及其制备方法。

  公开号：

  WO2013110643A1
• 作为产物：
  描述：

  1,2-二溴乙烷 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.0h， 以32%的产率得到4-(2-溴乙氧基)苯甲腈
  参考文献：
  名称：

  [EN] NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS
  [FR] NOUVEAUX COMPOSES D'OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT D'ARYTHMIES CARDIAQUES

  摘要：

  提供了具有公式I的化合物，其中R1、R2、R4、R41到R46、A、B和G的含义如描述中所示，在预防和治疗心律失常，特别是心房和心室心律失常方面是有用的。

  公开号：

  WO2005123747A1

文献信息

• Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)
  作者：Xiaoke Guo、Xianglei Ma、Qian Yang、Jing Xu、Lu Huang、Jianmin Jia、Jiaojiao Shan、Li Liu、Weilin Chen、Hongxi Chu、Jinlian Wei、Xiaojin Zhang、Haopeng Sun、Yiqun Tang、Qidong You

  DOI：10.1016/j.ejmech.2014.03.075

  日期：2014.6

  and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected

  Kv1.5钾通道是一种治疗房颤（AF）的有效且安全的治疗靶标，它是威胁人类的最常见心律不齐。本文中，通过从内部数据库中修改命中化合物7k，合成了48种衍生物，以通过全细胞膜片钳技术测定其Kv1.5抑制作用。选择了六种显示出比阳性化合物决奈达隆更好的效价的化合物用于其类药物性质的下一个评估。化合物8显示出平衡的溶解度和渗透性。它还显示出可接受的药效学特征，急性毒性非常低。考虑到所有这些数据，化合物8 可以作为开发用于治疗AF的新型治疗剂的有希望的先导。
• Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
  申请人：——

  公开号：US20020137766A1

  公开（公告）日：2002-09-26

  There is provided compounds of formula (I), wherein R 1 , R 2 , R 3 and R a to R h have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias, a process for the preparation of compounds of formula (I), and intermediate compounds.

  提供了一种通式(I)的化合物，其中R1、R2、R3以及Ra至Rh具有说明书中给出的含义，这些化合物在预防和治疗心律失常，特别是房性和室性心律失常方面具有用途；还提供了一种制备通式(I)化合物的方法以及中间体化合物。
• Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics
  作者：Dorota Maciejewska、Jerzy Żabinski、Pawel Kaźmierczak、Mateusz Rezler、Barbara Krassowska-Świebocka、Margaret S. Collins、Melanie T. Cushion

  DOI：10.1016/j.ejmech.2011.12.010

  日期：2012.2

  activity (1.33 μM), bears a sulfobenzene group at a nitrogen in the aliphatic linker. The alkanediamide-linked bisbenzamidines showed a moderate inhibition of ATP. Generally, the inclusion of a heteroatom in the aliphatic linker and absence of methoxy groups at the benzene rings were associated with higher activities in this assay. Of note, most of the compounds had little to no cytotoxicity in mammalian

  使用 2 个通用方案制备了一系列 20 种喷他脒类似物，这些方案在 ATP 生物测定中评估了脂肪族接头中的杂原子、磺基苯和链烷二酰胺基团以及连接到苯环上的甲氧基取代基对真菌病原体卡氏肺囊虫的功效。在 72 小时的测定期间，除了 20 种双脒中的一种外，所有的都降低了卡氏假单胞菌的 ATP 含量。最高的活性与缺乏甲氧基和存在 O、N 和 S 杂原子有关。活动（IC 50) 化合物 1、5、6、10 的范围为 1.1 至 2.13 μM。具有相似活性的化合物 11 (1.33 μM)，在脂肪族接头的氮原子上带有一个磺基苯基团。链烷二酰胺连接的双苯甲脒表现出对 ATP 的适度抑制。通常，在脂肪族接头中包含杂原子和在苯环上不存在甲氧基与该测定中更高的活性相关。值得注意的是，大多数化合物在哺乳动物细胞培养物中几乎没有细胞毒性。尽管不如其他喷他脒衍生物有效，但这些化合物有望减少哺乳动物宿主内的副作用。
• HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：HECKEL Armin

  公开号：US20130157981A1

  公开（公告）日：2013-06-20

  The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及一般式（I）的化合物，以及其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用可接受盐，具有有价值的药理特性，特别是对上皮钠通道具有抑制作用，以及其用于治疗疾病，特别是肺部和气道疾病的用途。
• Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein–Protein Interaction
  作者：Angelo Aguilar、Ke Zheng、Tianfeng Xu、Shilin Xu、Liyue Huang、Ester Fernandez-Salas、Liu Liu、Denzil Bernard、Kaitlin P. Harvey、Caroline Foster、Donna McEachern、Jeanne Stuckey、Krishnapriya Chinnaswamy、James Delproposto、Jeff W. Kampf、Shaomeng Wang

  DOI：10.1021/acs.jmedchem.9b00021

  日期：2019.7.11

  interaction is a promising new therapeutic strategy for the treatment of acute leukemia carrying MLL fusion (MLL leukemia). We describe herein our structure-based design, synthesis, and evaluation of a new class of small-molecule inhibitors of the menin-MLL interaction (hereafter called menin inhibitors). Our efforts have resulted in the discovery of highly potent menin inhibitors, as exemplified by compound

  抑制Menin混合谱系白血病（MLL）蛋白-蛋白相互作用是一种治疗带有MLL融合的急性白血病（MLL白血病）的有前途的新治疗策略。我们在本文中描述了我们基于结构的设计，合成和评估一类新型的Menin-MLL相互作用的小分子抑制剂（以下称为Menin抑制剂）。我们的努力导致发现了高效的menin抑制剂，如化合物42（M-89）所示。M-89以1.4 nM的Kd值与Menin结合，并在低纳摩尔浓度下有效地与细胞Menin蛋白结合。M-89抑制带有MLL融合的MV4; 11和MOLM-13白血病细胞系的细胞生长，其IC50值分别为25和55 nM，并且相对于缺乏MLL融合的HL-60白血病细胞系表现出> 100倍的选择性。与Menin的复合物中M-89的共晶体结构的确定为其高亲和力相互作用提供了结构基础。M-89的进一步优化可能会导致治疗MLL白血病的新疗法。